文献速递造血干细胞移植与细胞治疗白血病

针对白血病复发风险造血干细胞移植受者的T细胞免疫治疗开发

Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.
PubMed 文献 · Blood · 2017-10-19

本文开发了一种含4个组分的治疗性转基因T细胞免疫疗法,用于异基因造血干细胞移植后白血病复发的靶向治疗。该产品包含针对HA-1的TCR、CD8共受体、诱导型caspase 9安全开关和CD34-CD20表位,仅含记忆T细胞并排除初始T细胞以限制同种反应性。转导该转基因的CD4+和CD8+ T细胞对原发白血病显示出功能性反应。

要点

  • 构建含HA-1特异性TCR、CD8共受体、iCasp9安全开关和CD34-CD20表位的转基因。
  • T细胞产品包含HA-1 TCR CD4+和CD8+ T细胞,仅含记忆T细胞,排除初始T细胞。
  • 转导该转基因的CD4+和CD8+ T细胞对原发白血病显示功能性反应。

核心结论

  • 从次要H抗原特异性T细胞分离的TCR是开发靶向T细胞免疫治疗以管理移植后白血病复发的未开发资源。
  • 转导含HA-1 TCR转基因构建体的慢病毒载体的CD4+和CD8+ T细胞对原发白血病显示出功能性反应。

研究设计与样本

  • 本文描述了一种独特免疫疗法的开发过程,未报告研究设计类型、样本量或分组信息。

主要发现

  • 治疗性转基因包含4个组分:针对造血限制性白血病相关次要H抗原HA-1的TCR、促进I类限制性TCR在CD4+ T细胞中功能的CD8共受体、在毒性时消除HA-1 TCR T细胞的诱导型caspase 9安全开关、便于选择工程化细胞产品和追踪输注的HA-1 TCR T细胞的CD34-CD20表位。
  • T细胞产品包括HA-1 TCR CD4+ T细胞以增强HA-1 TCR CD8+ T细胞的持续性和功能,且仅包含记忆T细胞;排除初始T细胞以限制HA-1 TCR T细胞共表达的天然TCR介导的同种反应性潜力。
  • 转导含HA-1 TCR转基因构建体的慢病毒载体的CD4+和CD8+ T细胞对原发白血病显示出功能性反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leukemia relapse remains the major cause of allogeneic hematopoietic stem cell transplantation (HCT) failure, and the prognosis for patients with post-HCT relapse is poor. There is compelling evidence that potent selective antileukemic effects can be delivered by donor T cells specific for particular minor histocompatibility (H) antigens. Thus, T-cell receptors (TCRs) isolated from minor H antigen-specific T cells represent an untapped resource for developing targeted T-cell immunotherapy to manage post-HCT leukemic relapse. Recognizing that several elements may be crucial to the efficacy and safety of engineered T-cell immunotherapy, we developed a therapeutic transgene with 4 components: (1) a TCR specific for the hematopoietic-restricted, leukemia-associated minor H antigen, HA-1; (2) a CD8 coreceptor to promote function of the class I-restricted TCR in CD4+ T cells; (3) an inducible caspase 9 safety switch to enable elimination of the HA-1 TCR T cells in case of toxicity; and (4) a CD34-CD20 epitope to facilitate selection of the engineered cell product and tracking of transferred HA-1 TCR T cells. The T-cell product includes HA-1 TCR CD4+ T cells to augment the persistence and function of the HA-1 TCR CD8+ T cells and includes only memory T cells; naive T cells are excluded to limit the potential for alloreactivity mediated by native TCR coexpressed by HA-1 TCR T cells. We describe the development of this unique immunotherapy and demonstrate functional responses to primary leukemia by CD4+ and CD8+ T cells transduced with a lentiviral vector incorporating the HA-1 TCR transgene construct.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Dossa RG, Cunningham T, Sommermeyer D, et al. Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Blood. 2017. PMID: 29051183. doi:10.1182/blood-2017-07-791608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。